Endothelial Estrogen Receptor Alpha Inhibits Plaque Inflammation in Both Sexes [0.03%]
雌激素受体α抑制血管内皮和平滑肌细胞中的斑块炎症作用性别无差异
Nicole L Svedberg,Qing Lu,Alec Stepanian et al.
Nicole L Svedberg et al.
Background: Atherosclerotic plaque inflammation correlates with risk of rupture, causing myocardial infarction. Lower myocardial infarction risk in young women compared with men abates post-menopause, implicating ERs (est...
Inflammasome-Primed Neutrophils Aggravate Atherosclerosis in Cigarette Smoking [0.03%]
吸烟诱导的中性粒细胞通过炎性小体介导作用促进动脉粥样硬化形成
Dipanjan Chattopadhyay,Nitin Nitin,Robert M Jaggers et al.
Dipanjan Chattopadhyay et al.
Background: Cigarette smoking (CS) is a major risk factor for cardiovascular disease through chronic inflammation. While its pulmonary effects are well established, the mechanisms linking lung inflammation to vascular inj...
Stephen J Nicholls,Kausik K Ray,Adam J Nelson et al.
Stephen J Nicholls et al.
CETP (cholesteryl ester transfer protein) plays an important role in lipid metabolism, facilitating the exchange of esterified cholesterol for triglycerides between lipoproteins. Genetic and cohort studies have demonstrated the presence of ...
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering [0.03%]
apoB残留物质降低作用的新老治疗靶点
Daniel Gaudet,Miriam Larouche,Frederick J Raal et al.
Daniel Gaudet et al.
ApoB is the structural protein of all atherogenic lipoproteins, including VLDLs (very-low-density lipoproteins), IDLs (intermediate-density lipoproteins), LDLs (low-density lipoproteins), chylomicron remnants, as well as Lp(a) (lipoprotein[...
Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis [0.03%]
GLP-1轴在血管重塑及脂蛋白代谢中的作用研究进展及其心血管风险效应
Giuliana G Repetti,E Dale Abel,Peter Tontonoz et al.
Giuliana G Repetti et al.
Obesity and its cardiometabolic sequelae remain a public health challenge. GLP-1R (glucagon-like peptide-1 receptor) agonists have emerged as a transformative therapy to combat obesity. Although weight loss is a key part of how these drugs ...
Ira J Goldberg,Martin E Young,P Christian Schulze et al.
Ira J Goldberg et al.
Although studied for decades, metabolic therapies that target cardiac lipid metabolism are underdeveloped, and most approaches have thus far failed as a heart failure treatment. In contrast, new therapies for diabetes and obesity are widely...
Keith L Saum,Subramaniam Pennathur,Jenny E Kanter
Keith L Saum
Cardiovascular disease and chronic kidney disease are highly interconnected, with declining kidney function markedly increasing cardiovascular risk. Chronic kidney disease profoundly disrupts lipoprotein metabolism, leading to qualitative a...
Lipoproteins in Cardiovascular Disease: Building on Successes to Meet Future Challenges [0.03%]
脂蛋白与心血管疾病研究：发扬成绩，迎接挑战
Karin E Bornfeldt
Karin E Bornfeldt
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease [0.03%]
肝脏脂蛋白产生、心血管代谢表型以及脂肪肝病亚型的关系研究
Nicholas O Davidson
Nicholas O Davidson
Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts more than a third of adults worldwide. The burgeoning epidemic of MASLD has led to increases in atherosclerotic cardiovascular disease (CVD), which is the leading caus...
Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside [0.03%]
糖尿病患者的富含甘油三酯脂蛋白代谢与心血管风险：从床边到实验台再到床边
Henry N Ginsberg,Karin E Bornfeldt
Henry N Ginsberg
Type 1 diabetes and type 2 diabetes are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), manifested as myocardial infarction, ischemic stroke, and peripheral artery disease. The increased ASCVD risk in di...